MRD is the lowest tumor burden that cannot be detected by standard imaging and clinical examination. The presence of MRD after surgery or completion of chemotherapy is the strongest predictor of relapse risk.
Where Liquid Biopsy Fits in MRD Detection
- CTC-based MRD: assessment of post-surgical residual disease by the presence/absence of CTCs in blood
- ctDNA-based MRD: post-treatment monitoring with ultra-sensitive NGS targeting tumor-specific mutations
- Longitudinal monitoring: early relapse detection through periodic blood draws after treatment
Clinical Applications (Research)
- Colorectal cancer: post-surgical ctDNA positivity strongly correlates with relapse risk
- Breast cancer: CTC counts after neoadjuvant therapy correlate with pathological complete response
- Lung cancer: early relapse detection through post-surgical MRD monitoring
Research Scope
Our MRD assessment services are for research use only. No clinical decision-support patient monitoring is performed; they are used for endpoint analysis or biomarker discovery in clinical studies.
For your MRD-based liquid biopsy project, get in touch with us.
Rx-only——処方箋制のスクリーニング検査. Galleri® は診断検査ではありません。陽性結果は癌の診断を意味せず、陰性結果は癌を除外するものではありません。本検査は、医師が推奨する定期的な癌スクリーニングの代わりになるものではありません。 Galleri® はすべての癌種を検出するものではありません。